A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Aragon Pharmaceuticals; Janssen Research & Development
- 23 May 2019 Planned End Date changed from 3 Jun 2019 to 3 Dec 2019.
- 13 Dec 2018 Planned primary completion date changed from 30 Nov 2018 to 3 Jun 2019.
- 12 Oct 2018 Planned End Date changed from 30 Nov 2018 to 3 Jun 2019.